González-Alvaro I, Muñoz C, García-Vicuña R, Sabando P, Cabañas C, Sánchez-Madrid F, Díaz-González F
Hospital La Princesa, Universidad Autónoma de Madrid, Spain.
Arthritis Rheum. 1998 Sep;41(9):1677-88. doi: 10.1002/1529-0131(199809)41:9<1677::AID-ART20>3.0.CO;2-4.
To study the effect of nonsteroidal antiinflammatory drugs (NSAIDs) on the adhesion of peripheral blood lymphocytes (PBL) to activated human umbilical vein endothelial cells (HUVEC) under conditions that resemble blood flow.
Assays of adhesion of PBL to HUVEC or recombinant vascular cell adhesion molecule 1 (rVCAM-1), intercellular adhesion molecule 1 (ICAM-1), and E-selectin were performed under continuous rotation at 37 degrees C. The phenotype of PBL subpopulations attached was characterized by flow cytometry. Lymphocytes were pretreated with different doses (5-100 microg/ml) of aceclofenac, diclofenac, indomethacin, or piroxicam or with inhibitory monoclonal antibodies (MAb) prior to the adhesion assays. The effect of NSAIDs on lymphocyte adhesion molecules was assessed by flow cytometry. To determine whether NSAIDs interfere with the affinity state of very late activation antigen 4 (VLA-4) integrin, we studied the effect of these drugs on the appearance of a beta1 activation-dependent epitope recognized by the HUTS21 MAb both on human T lymphoblasts and on synovial fluid lymphocytes (SFL).
In the flow-resembling model, PBL-HUVEC adhesion was mainly mediated by the VLA-4/ VCAM-1 adhesion pathway. The major PBL subset attached was the CD3+, CD45RO+ memory T cell, with CD49d(high) expression. Aceclofenac, diclofenac, and indomethacin, but not piroxicam, were able to inhibit PBL adhesion to HUVEC or rVCAM-1. However, the quantitative expression of VLA-4 was not affected by treatment of PBL with any of the NSAIDs studied. On T lymphoblasts and SFL, mostly CD45RO+ cells, the expression of the beta1 activation-dependent epitope detected by HUTS21 MAb was significantly decreased by aceclofenac, diclofenac, and indomethacin.
Some NSAIDs are able to inhibit the adhesion of PBL to HUVEC under conditions that resemble blood flow by interfering with the conformational change in VLA-4 that increases its affinity for VCAM-1.
研究在模拟血流的条件下,非甾体抗炎药(NSAIDs)对外周血淋巴细胞(PBL)与活化的人脐静脉内皮细胞(HUVEC)黏附的影响。
在37℃连续旋转条件下进行PBL与HUVEC或重组血管细胞黏附分子1(rVCAM-1)、细胞间黏附分子1(ICAM-1)及E-选择素的黏附试验。通过流式细胞术对黏附的PBL亚群的表型进行鉴定。在黏附试验前,用不同剂量(5 - 100μg/ml)的醋氯芬酸、双氯芬酸、吲哚美辛或吡罗昔康或抑制性单克隆抗体(MAb)对淋巴细胞进行预处理。通过流式细胞术评估NSAIDs对淋巴细胞黏附分子的影响。为确定NSAIDs是否干扰极晚期活化抗原4(VLA-4)整合素的亲和状态,我们研究了这些药物对人T淋巴母细胞和滑液淋巴细胞(SFL)上由HUTS21 MAb识别的β1活化依赖性表位出现的影响。
在模拟血流模型中,PBL-HUVEC黏附主要由VLA-4/VCAM-1黏附途径介导。黏附的主要PBL亚群是CD3 +、CD45RO +记忆T细胞,表达CD49d(高)。醋氯芬酸、双氯芬酸和吲哚美辛能够抑制PBL与HUVEC或rVCAM-1的黏附,但吡罗昔康不能。然而,所研究的任何一种NSAIDs处理PBL均不影响VLA-4的定量表达。在T淋巴母细胞和SFL(大多为CD45RO +细胞)上,醋氯芬酸、双氯芬酸和吲哚美辛可使HUTS21 MAb检测到的β1活化依赖性表位的表达显著降低。
一些NSAIDs能够在模拟血流的条件下,通过干扰VLA-4的构象变化(这种变化会增加其对VCAM-1的亲和力)来抑制PBL与HUVEC的黏附。